Is AtaiBeckley Inc. (ATAI) Stock a Psychedelic Medicine Opportunity Ahead of Phase 2 Results?

We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best psychedelic stocks on our list.

TheFly reported on July 7 that Canaccord increased its price target on ATAI to $17 from $15 while maintaining a Buy rating on the shares. The firm revised its model following the company’s announcement that it had completed dosing the final participant in the Elumina Phase 2 study evaluating VLS-01, a DMT buccal film, for treatment-resistant depression. Canaccord noted that ATAI remains on track to report topline results in the fourth quarter of 2026.

On July 6, AtaiBeckley Inc. (NASDAQ:ATAI) announced the completion of patient dosing in its Phase 2b Elumina clinical trial evaluating VLS-01 in adults with treatment-resistant depression. The multi-center, double-blind, placebo-controlled study enrolled 156 participants, with topline results expected in the fourth quarter of 2026. The company plans to progress VLS-01 into Phase 3 development for major depressive disorder, while generalized anxiety disorder remains a potential future indication. ATAI stated that VLS-01, alongside BPL-003, which is currently in Phase 3 development for treatment-resistant depression with Breakthrough Therapy Designation, could support a broader approach to treating mood and anxiety disorders.

AtaiBeckley Inc. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company formed through the merger of Atai Life Sciences and Beckley Psytech, focused on developing fast-acting, long-lasting psychedelic-based treatments for difficult-to-treat mental health disorders.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.